CODX Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -12425.36%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 1792.03%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.2500 which suggests that it could grow by 223.22%. Given that Co-Diagnostics, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Perspective Therapeutics, Inc..

Co-Diagnostics, Inc. has a beta of 1.248, which suggesting that the stock is 24.773% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 41.58x versus 256.98x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CareDx, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of 1.67%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat CareDx, Inc.'s return on equity of 21.1%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 1792.03%. On the other hand CareDx, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 7.06%. Given that Co-Diagnostics, Inc. has higher upside potential than CareDx, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than CareDx, Inc..

Co-Diagnostics, Inc. has a beta of 1.248, which suggesting that the stock is 24.773% more volatile than S&P 500. In comparison CareDx, Inc. has a beta of 2.490, suggesting its more volatile than the S&P 500 by 148.978%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CareDx, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. CareDx, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than CareDx, Inc. quarterly revenues of $100.1M. Co-Diagnostics, Inc.'s net income of -$5.9M is lower than CareDx, Inc.'s net income of $1.7M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while CareDx, Inc.'s PE ratio is 17.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 41.58x versus 3.18x for CareDx, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of 12.65%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Electromed, Inc.'s return on equity of 18.89%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 1792.03%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 20.52%. Given that Co-Diagnostics, Inc. has higher upside potential than Electromed, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Electromed, Inc..

Co-Diagnostics, Inc. has a beta of 1.248, which suggesting that the stock is 24.773% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Co-Diagnostics, Inc.'s net income of -$5.9M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 32.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 41.58x versus 3.98x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -27.41%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 1792.03%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $41.50 which suggests that it could grow by 1.05%. Given that Co-Diagnostics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Co-Diagnostics, Inc. is more attractive than Twist Bioscience Corp..

Co-Diagnostics, Inc. has a beta of 1.248, which suggesting that the stock is 24.773% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.191, suggesting its more volatile than the S&P 500 by 119.099%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 41.58x versus 6.55x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.